Prosecution Insights
Last updated: November 04, 2026
Application No. 18/023,581

METHOD OF ASSESSING THE CIRCADIAN RHYTHM OF A SUBJECT HAVING CANCER AND/OR ASSESSING A TIMING OF ADMINISTRATION OF A MEDICAMENT TO SAID SUBJECT HAVING CANCER

Final Rejection §101§103§112
Filed
Feb 27, 2023
Priority
Aug 27, 2020 — EU 20193231.6 +1 more
Examiner
PULLIAM, JOSEPH CONSTANTINE
Art Unit
1687
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Angela Moreira Borralho Relógio
OA Round
2 (Final)
38%
Grant Probability
At Risk
3-4
OA Rounds
1y 3m
Est. Remaining
72%
With Interview

Examiner Intelligence

Grants only 38% of cases
38%
Career Allowance Rate
25 granted / 65 resolved
-21.5% vs TC avg
Strong +33% interview lift
Without
With
+33.2%
Interview Lift
resolved cases with interview
Typical timeline
4y 11m
Avg Prosecution
24 currently pending
Career history
102
Total Applications
across all art units

Statute-Specific Performance

§101
33.2%
-6.8% vs TC avg
§103
27.6%
-12.4% vs TC avg
§102
4.2%
-35.8% vs TC avg
§112
26.5%
-13.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 65 resolved cases

Office Action

§101 §103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Claims The claim set received 27 July 2026 have been entered into the application. Claims 13 and 16 are cancelled. Claims 21-23 are new. Claims 1-12, 14-15, and 17-23 are pending. Priority This Application is a 371 of PCT/EP2021/073802 filed 20 August 2021 which claims foreign benefit to EP20193231.6 filed 27 August 2020. Acknowledgment is made of applicant’s claim for foreign priority under 35 U.S.C. 119 (a)-(d). The certified copy has been filed in parent Application No. EP20193231.6 filed 27 August 2020. Election/Restrictions Claims 11-12, 14-15, 18-20, and 23 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on 13 November 2025. Claim Objections The objection to claims 1, 7-8, 10, and 16 in the Office Action mailed 27 March 2026 is withdrawn in view of the amendments filed 27 July 2026. The objection to claim 1 in the Office Action mailed 27 March 2026 is withdrawn in view of the amendments filed 27 July 2026. The objection to claim 6 in the Office Action mailed 27 March 2026 is withdrawn in view of the amendments filed 27 July 2026. The objection to claim 7 in the Office Action mailed 27 March 2026 is withdrawn in view of the amendments filed 27 July 2026. The objection to claim 10 in the Office Action mailed 27 March 2026 is withdrawn in view of the amendments filed 27 July 2026. The objection to claim 16 in the Office Action mailed 27 March 2026 is withdrawn in view of the amendments filed 27 July 2026 because the claim was cancelled. Claim Rejections - 35 USC § 112 SC § 112(b) The rejection of claim 1 under 35 U.S.C § 112(b) in the Office Action mailed 27 March 2026 is withdrawn in view of the amendments filed 27 July 2026. The rejection of claim 8 under 35 U.S.C § 112(b) in the Office Action mailed 27 March 2026 is withdrawn in view of the amendments filed 27 July 2026. The rejection of claim 10 under 35 U.S.C § 112(b) in the Office Action mailed 27 March 2026 is withdrawn in view of the amendments filed 27 July 2026. 35 USC § 112(d) The rejection of claim 13 under 35 U.S.C § 112(d) in the Office Action mailed 27 March 2026 is withdrawn in view of the amendments filed 27 July 2026 because the claim was cancelled. Claim Rejections - 35 USC § 101 The instant rejection is maintained for reason for record in the Office Action mailed 27 March 2026 and modified in view of the amendments filed 27 July 2026. It is noted the amendments received 27 July 2026 are necessitated by new ground(s) of rejection. 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claims 1-10, 17, and 21-22 rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. Step 1 - Process, Machine, Manufacture or Composition Claims 1-10, 17, and 21-22 are drawn to a method, so a process. Step 2A Prong I - Identification of an Abstract Idea Claim 1 recites: measuring gene expression of the following genes: at least two core-clock member genes from the group of step (a), at least one gene involved in the metabolism of a medicant to be administered including Ces2 (b), and at least one drug target gene that is the target of the administered medicant (c). This step can be performed in the human mind by organizing information (i.e., gene expression data) of genes (i.e., at least two core-clock member genes, genes involved in medication metabolism, drug target gene) to determine gene expression and is therefore an abstract idea. Here, the term is “measuring” is broad and reads on abstract ideas. Furthermore, the measuring step is broad and generic and reads on abstract ideas. For example, a claim to "collecting information (i.e., measuring), analyzing it, and displaying certain results of the collection and analysis," where the data analysis steps are recited at a high level of generality such that they could practically be performed in the human mind, Electric Power Group v. Alstom, S.A., 830 F.3d 1350, 1353-54, 119 USPQ2d 1739, 1741-42 (Fed. Cir. 2016). assessing and predicting by means of a computational step based on said expression levels of said genes over the day the circadian rhythm of said subject and/or assessing a timing of administration of said medicament to said subject, comprising assessing the optimal time of administration of said medicament to said subject and/or assessing the non-optimal time of administration of said medicament to said subject. This step can be performed in the human mind by observing, judging, and evaluating genetic data (i.e., gene expression levels) for assessing and predicting the circadian rhythm of a subject and is therefore an abstract idea. This step can further be performed in the human mind by observing, judging, and evaluating information (i.e., timing of administration of medications) for assessing optimal and non-optimal time of administration and therefore reads on abstract ideas. This step encompasses performing mathematical computations on gene expression data which reads on abstract ideas. wherein assessing the timing comprises allocating time-dependent numerical values to said gene expressions This step can be performed in the human mind by organizing information (i.e., time-dependent numerical values) to gene expression for assessing said time-dependent numerical values and is therefore an abstract idea. This step encompasses performing mathematical computations for allocating time values (i.e., quantitative data) to and with gene expression data which encompasses abstract ideas. selecting a minimum or maximum of a determined ratio to indicate the optimal or non-optimal administration time. This step can be performed in the human mind by observing, comparing, and evaluating information (i.e., a minimum or maximum of a determined ratio) for indicating a optimal or non-optimal administration time and is therefore an abstract idea. This step encompasses using mathematical concepts of using minimum or maximum of a determined ratio (i.e., quantitative data/numerical values) which reads on abstract ideas. Claims 4-10, 17, and 22 are further drawn to limitations that describe the abstract ideas of claim 1 and are therefore also abstract ideas. Step 2A Prong Two: Consideration of Practical Application Claim 1 does not contain any additional elements that integrate the recited judicial exception into a practical application. Here, in the instant case, the claims merely set forth a method data analysis for assessing and predicting and assessing the timing of medication administration. As such, practicing the claims merely results in the assessing and predicting of information and assessing optimal and non-optimal timing of medication administration. Such a result only produces information and does not provide for a practical application in the physical-realm of physical things and acts, i.e., the claims do not utilize the data generated by the judicial exception to affect any type of change. See MPEP 2106.04(a)(2)(A)(iv). Thus, because a judicial exception of the claims, alone, is not eligible subject matter and the claims do not encompass any additional elements other than of extra-solution activities (i.e., providing samples (saliva samples), PCR, gene expression (Nanostring), medications) and tangential computer elements, the claims do not construct a practical application and/or improvement to technology as set forth below. See MPEP 2106.04(d)(III), 2106.05(a). Therefore, the claims, under Step 2A Prong II of the 101 analyses, are not patent ineligible. As such, the claims do not utilize the obtained saliva samples, determined gene expression levels, and the assessed and predicted data, and the abstract ideas to construct a practical application such as treating a subject, transformation of matter, or improving upon an existing technology. Claims 8 recite “training a machine learning algorithm…” while claims 9 and 17 recite “…wherein the prediction computational model is based on machine learning…”. It is noted that the claims do not recite any computer limitations for performing the machine learning processes/computational steps. Here, even though the claimed steps utilize a “machine learning algorithm/model based on machine learning”, the machine learning models/algorithms are broadly and generically recited and read on mere instructions to implement an abstract idea on a generic computer and read on mathematical/statistical computations (i.e., k-nearest neighbors, support vector machine). See 2024 Subject Matter Eligibility Update (AI) [Example 47 Claim 2] and MPEP 2106.04(a)(2)(III)(C) (1-3) and 2106.05(f). Furthermore, and for sake of compact prosecution, even if the machine learning algorithm/model is also considered an additional element, the machine learning models/algorithms (MLM/A) are used to generally apply the abstract idea without limiting how the trained (MLM/a) functions. The MLM/A is described at a high level such that it amounts to using a computer with a generic MLM/A to apply the abstract idea. These limitations only recite the outcomes for “training a machine learning algorithm…to form the network computation model (claims 8)” without any details about how to form a network computation model by training machine algorithm using derived characteristic data and recites the outcomes for “fitting a prediction computational model…wherein the computational model is based on machine learning…(claims 9 and 17)” without any details about how the prediction computational models (i.e., machine learning: clustering and classification models) are fitted using data obtained from fitted periodic functions and/or said network computational model which does not integrate the judicial exception into a practical application or provide significantly more because this type of recitation is equivalent to the words "apply it". See 2024 Subject Matter Eligibility Update (AI) [Example 47 Claim 2] and MPEP 2106.05(f). Claim 22 was added to recite “wherein the training the machine learning algorithm comprises optimizing the machine learning algorithm in terms of the representation of the periodic time course of the expression level for the at least one further gene.” It is noted that the claims do not recite any computer limitations for performing the machine learning processes/computational steps. Here, even though the claimed steps utilize a “training the machine learning algorithm (MLA) comprising optimizing the MLA”, the machine learning models/algorithms are broadly and generically recited and read on mere instructions to implement an abstract idea on a generic computer and read on mathematical/statistical computations (i.e., k-nearest neighbors, support vector machine). For example, training a MLA by optimizing data encompasses taking existing information (i.e., representation of the periodic time course of the expression level for at least one gene) and manipulating the information via mathematical correlations/functions (i.e., optimizing methods) for organizing data into a new form (i.e., refined/optimized time course gene expression data) which reads on abstract ideas. See 2024 Subject Matter Eligibility Update (AI) [Example 47 Claim 2] and MPEP, 2106.04(a)(2)(A)(iv), 2106.04(a)(2)(III)(C) (1-3) and 2106.05(f). This judicial exception is not integrated into a practical application because the claims do not meet any of the following criteria: An additional element reflects an improvement in the functioning of a computer, or an improvement to other technology or technical field; an additional element that applies or uses a judicial exception to effect a particular treatment or prophylaxis for a disease or medical condition; an additional element implements a judicial exception with, or uses a judicial exception in conjunction with, a particular machine or manufacture that is integral to the claim; an additional element effects a transformation or reduction of a particular article to a different state or thing; and an additional element applies or uses the judicial exception in some other meaningful way beyond generally linking the use of the judicial exception to a particular technological environment, such that the claim as a whole is more than a drafting effort designed to monopolize the exception. Step 2B - Consideration of Additional Elements and Significantly More The claimed method also recites "additional elements" that are not limitations drawn to an abstract idea. The additional element of providing samples (i.e., saliva) of claims 1 and 21 does not add significantly more than the recited judicial exception because using sample collected at several time points to provide a source of nucleic acids that is subsequently processed and analyzed by the abstract ideas is well-known and conventional. See MPEP 21406.05(d)(II)(i-iii, v, vii) and 2106.05(g). To provide evidence of conventionality of using saliva samples, Gozu et al. (Gozu) discloses measuring gene expression levels in sputum/saliva over time and measuring the circadian rhythm based on the gene expression levels [Gozu, claims 1-2]. (Int. Patent Pub.: WO 2011114732, Patent Pub Date: 22 September 2011). The additional element of using clinical/laboratory methods (Nanostring, RT-PCR, sequencing and microarray) of claims 2-3 does not add significantly more than the recited judicial exception because using techniques (Nanostring, RT-PCR, sequencing and microarray) to obtain nucleic data from samples that is subsequently analyzed by the abstract ideas is well-known and conventional extra-solution activity. See MPEP 21406.05(d)(II)(i-iii, v, vii) and 2106.05(g). To provide evidence of conventionality of using the NanoString method for determining gene expression levels, Braun et al. (Braun) discloses using NanoString for measuring biomarkers [Braun, disclosure, page 6 right col para 0047]. (U.S Patent Pub: US 2018/0357360: Patent Pub Date: 13 December 2018). In conclusion, and when viewed as a whole, these additional claim element(s) do not provide meaningful limitation(s) to transform the abstract idea recited in the instantly presented claims into a patent eligible application of the abstract idea such that the claim(s) amounts to significantly more than the abstract idea itself. Therefore, the claim(s) are rejected under 35 U.S.C. 101 as being directed to non-statutory subject matter. Response to Arguments The Applicant's arguments filed 27 March 2026 have been fully considered but they are not persuasive. The Applicant states the claims require at least two samples of saliva at different points in the day which requires real-world steps. The Applicant states the claims require two physical samples and requires measuring the gene expression, and the computational step is clearly integrated into the real-world claim features [remarks, page 10]. The Applicant points to Ex parte Desjardin and MPEP 2106.05(a) for guidance. The Applicant states the claims integrate the abstract idea into a practical application, i.e., determining the subject-specific optimal (and non-optimal) time to administer the medicament is itself a practical application. In response, the argument is not persuasive because using saliva samples as a source of nucleic acid data is an extra solution activity. See MPEP 2106.05(d)(II). Furthermore, the measuring step is broad and generic and reads on abstract ideas. For example, a claim to "collecting information (i.e., measuring), analyzing it, and displaying certain results of the collection and analysis," where the data analysis steps are recited at a high level of generality such that they could practically be performed in the human mind, Electric Power Group v. Alstom, S.A., 830 F.3d 1350, 1353-54, 119 USPQ2d 1739, 1741-42 (Fed. Cir. 2016). Also, a claims drawn to collecting and comparing known information, which are steps that can be practically performed in the human mind, Classen Immunotherapies, Inc. v. Biogen IDEC, 659 F.3d 1057, 1067, 100 USPQ2d 1492, 1500 (Fed. Cir. 2011). See MPEP 2106.04(a)(2)(III)(A). Additionally, even if the measuring step reads on an additional element for measuring biomarkers, using additional elements to measure biomarkers in samples is an extra-solution activity. Thus, the saliva samples and the measuring step (i.e., abstract idea) are insufficient to provide a practical application or an improvement to technology under Step 2A Prong II. The Applicant states that the claimed computational step is performed by a processor/computer, and clearly not something that is reasonably possible to be performed by a human mind. The Applicant states the claim does not "merely produce information," it begins with and processes physical saliva samples and yields a treatment relevant determination of when the drug should be given [remarks, page 10]. The Applicant states the claims should be understood to provide an improvement in the functioning of a computer, or an improvement to other technology or technical field (i.e., the technology or technical field of administration of cancer chronotherapy) [remarks, page 10]. . The Applicant points to the MPEP 2106.04(d)(I) and 2106.05(a) for guidance [remarks, page 10]. The Applicant states there is no basis for restricting this 101 consideration only to the computer fields and the MPEP (as cited above) explicitly says that it also applies to "other technology or technical field [remarks, page 11]. The Applicant provides a post filing date reference: Malhan D, Hesse J, Nelson N, et al. Circadian rhythm disruption by PARP inhibitors correlates with treatment toxicity in patients with ovarian cancer and is a predictor of side effects. EBioMedicine. 2025;117: 105764 (attached with this response) [remarks, page 15]. The Applicant states the study demonstrates correlations between ARNTLI (BMALI) gene expression, cortisol acrophases, chronotype, sleep timing, and other behavioral timing parameters, thereby independently confirming that the analytical methods disclosed in the present invention accurately capture physiologically relevant circadian information. The Applicant states subsequent peer-reviewed validations (attached) provide objective evidence that the claims constitute a practical technical application of molecular circadian analysis and is neither speculative nor merely directed to an abstract mathematical concept [remarks, page 16]. The Applicant states “claimed computational analyses cannot be performed solely as a mental process, but require laboratory-derived molecular gene expression measurements obtained from physical saliva samples, followed by computer-implemented computational analyses to generate individualized circadian predictions. This clearly satisfies 35 USC 101.” [remarks, page 17: 1 page remarks received 27 July 2026]. In response, using a computer for processing data does not preclude the claims from being performed in the human mind. See MPEP 2106.04(a)(2)(III)(C)(III). Moreover, there are no claimed computer elements recited in the claims. Here, the claims utilize extra-solution activities for processing saliva samples to obtain biomarker data related to a drug administered to a patient (i.e., administered drugs reads extra-solution data gathering activities) and assessing the obtained biomarker data for assessing optimal and non-optimal times of medication administration (i.e., data analysis step). Thus, the additional elements of the claims are not sufficient to construct a practical application of the judicial exception as the claims do not contain any additional elements that integrate the data analysis (i.e., judicial exception) into a practical application and/or improvement to technology such as treating a subject, transformation of matter, and/or improving an existing technology. See MPEP 2106.04(a)(2)(A)(iv) and 2106.04(d). As such, the claims are drawn to producing information (i.e., assessment of medication administration timing). Therefore, because a judicial exception of the claims, alone, is not eligible subject matter and the claims do not encompass any additional elements other than of extra-solution activities (i.e., providing samples (saliva samples), administering a medication, PCR, gene expression (Nanostring), medications) and tangential computer elements, the claims do not construct a practical application and/or provide an improvement to technology. See MPEP 2106.04(d)(III) and 2106.05(a). Therefore, the claims, under Step 2A Prong II of the 101 analyses, are not patent ineligible. With respect to the improvement of technology and/or a technical field, the argument is not persuasive because the claims do not recite administering a chronotherapy to which gene expression and time of administration can be correlated but recites assessing gene expression levels and assessing “timing of administration” for assessing the optimal and non-optimal timing of medicant administration (i.e., data analysis steps). It is noted that the judicial exception alone cannot provide an/said improvement. See MPEP 2106.04(d)(III) and 2106.05(a) “the judicial exception alone cannot provide the improvement. The improvement can be provided by one or more additional elements. In addition, the improvement can be provided by the additional element(s) in combination with the recited judicial exception.” Here, the claims the are drawn to “assessing gene expression levels and assessing “timing of administration” of a medication for assessing the optimal and non-optimal timing of administration” (i.e., judicial exception) which encompasses mere data analysis steps without the integration of any additional elements other than extra-solution activities (i.e., providing samples (saliva samples), PCR, gene expression (Nanostring), medications) and tangential computer elements. Thus, because the claims do not integrate the judicial exception with any additional elements, as noted above, the claims cannot provide an improvement to technology or a technical field. Moreover, with respect to the correlation (i.e., between ARNTLI (BMALI) gene expression, cortisol acrophases, chronotype, sleep timing, and other behavioral timing parameters) of the claims, the correlation is not integrated with any additional elements so that to integrate the natural correlation (i.e., genotype/phenotype of a subject) and judicial exception (i.e., assessed gene expression levels and assessed optimal and non-optimal times of administration) into practical application or an improvement to technology. Additionally, an inventive concept “cannot be furnished by the unpatentable law of nature (or natural phenomenon or abstract idea). Instead, an “inventive concept” is furnished by an element or combination of elements that is recited in the claim in addition to (beyond) the judicial exception, and is sufficient to ensure that the claim as a whole amounts to significantly more than the judicial exception itself. Here, however, the claims encompass additional elements, alone and in combination, that do not provide an “inventive concept” because the additional elements are routine and conventional. See MPEP 2106.05(I). Therefore, the claims are patent ineligible. Regarding Malhan, the reference was not provided by the Applicant and is not in the application. Additionally, as noted above in Step2A Prong II of the 101 analyses above, because a judicial exception of the claims, alone, is not eligible subject matter and the claims do not encompass any additional elements other than of extra-solution activities (i.e., providing samples (saliva samples), administering a medication, PCR, gene expression (Nanostring), medications), the claims do not construct a practical application and/or provide an improvement to technology. See MPEP 2106.04(d)(III), 2106.05(a). Claim Rejections - 35 USC § 103 The instant rejection is maintained for reason for record in the Office Action mailed 27 March 2026 and modified in view of the amendments filed 27 July 2026. It is noted the amendments received 27 July 2026 are necessitated by new ground(s) of rejection. The rejection of claim(s) 1-5, and 7 under 35 U.S.C. 103 as being unpatentable over Ballesta et al. (PLoS computational biology, 2011-09, Vol.7 (9), p.e1002143) (Cited in the IDS received 27 February 2023: NPL Citation No.: 4) in view of Wittenbrink et al. (The Journal of clinical investigation, 2018-09, Vol.128 (9), p.3826-3839) in the Office Action mailed 27 March 2026 is withdrawn in view of the amendments filed 27 July 2026 because the claim was cancelled. The rejection of claim(s) 6, 8, and 16 under 35 U.S.C. 103 as being unpatentable over Ballesta in view of Wittenbrink, as applied to claims 1-5 and 7, and in further view of Hughey et al. (Nucleic acids research, 2016-05, Vol.44 (8), p.e80-e80) in the Office Action mailed 27 March 2026 is withdrawn in view of the amendments filed 27 July 2026. Conclusion Claims 1-10, 17, and 21-22 are rejected. No claims are allowed. Finality THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Inquiries Any inquiry concerning this communication or earlier communications from the examiner should be directed to JOSEPH C PULLIAM whose telephone number is (571)272-8696. The examiner can normally be reached 0730-1700 M-F. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Karlheinz Skowronek can be reached at (571) 272-9047. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /J.C.P./Examiner, Art Unit 1687 /Anna Skibinsky/ Primary Examiner, AU 1635
Read full office action

Prosecution Timeline

Feb 27, 2023
Application Filed
Mar 27, 2026
Non-Final Rejection mailed — §101, §103, §112
Jul 27, 2026
Response Filed
Oct 20, 2026
Final Rejection mailed — §101, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12749556
SELECTION OF CANCER MUTATIONS FOR GENERATION OF A PERSONALIZED CANCER VACCINE
5y 6m to grant Granted Sep 29, 2026
Patent 12731660
METHODS AND SYSTEMS FOR DESIGNING PHAGE COCKTAILS
3y 7m to grant Granted Sep 08, 2026
Patent 12706175
METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS
6y 8m to grant Granted Aug 11, 2026
Patent 12700475
SYSTEMS AND METHODS FOR DISSECTING HETEROGENEOUS CELL POPULATIONS
6y 10m to grant Granted Aug 04, 2026
Patent 12694947
METHODS AND SYSTEMS FOR ASSESSING INFLAMMATORY DISEASE WITH DEEP LEARNING
6y 3m to grant Granted Jul 28, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
38%
Grant Probability
72%
With Interview (+33.2%)
4y 11m (~1y 3m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 65 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month